XML 28 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jul. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Mar. 31, 2018
Nov. 01, 2016
Summary Of Significant Accounting Policies [Line Items]              
Cash and cash equivalents   $ 35,224,000 $ 47,338,000 $ 35,224,000 $ 47,338,000 $ 43,726,000  
Restricted cash   127,000 127,000 127,000 127,000 127,000  
Accumulated deficit   $ (253,772,000)   (253,772,000)   $ (234,120,000)  
Cash flow from operations       $ 15,298,000 23,246,000    
Issuance of common stock   117,769,919   117,769,919   111,032,957  
Deferred revenue   $ 580,000   $ 580,000   $ 668,000  
Revenue recognized       136,000      
Revenue recognized under grants   779,000 1,153,000 2,411,000 3,498,000    
Cost of revenues   100,000 200,000 400,000 700,000    
Dilutive effect   0 0 $ 0 $ 0    
Common stock equivalents excluded from computing diluted net loss per share       15,600,000 14,000,000    
Accounting Standards Update 2016-18 [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Restricted cash             $ 100,000
NIH Research Grants Two [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Revenue recognized under grants $ 1,657,000            
Grant revenue funding period 3 years            
Product [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Product return revenue       $ 0      
Grants [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Revenue recognized under grants   66,000 260,000 574,000 $ 409,000    
Grants [Member] | NIH Research Grants Two [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Revenue recognized under grants   66,000 $ 260,000 574,000 $ 409,000    
Research and Development Services [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Deferred revenue   $ 580,000   $ 580,000   $ 687,000  
At-The-Market Facility [Member]              
Summary Of Significant Accounting Policies [Line Items]              
Issuance of common stock   5,560,514   5,560,514      
Gross proceeds from sale of common stock shares       $ 6,900,000